Antimicrobial prophylaxis for children with vesicoureteral reflux

Jonathan C. Craig, Gabrielle J. Williams, Elisabeth M. Hodson

Research output: Contribution to journalLetter

23 Citations (Scopus)


To the Editor

The Randomized Intervention for Children with Vesicoureteral Reflux (RIVUR) trial reported by Hoberman et al. (June 19 issue)1 was similar to our Prevention of Recurrent Urinary Tract Infection in Children with Vesicoureteric Reflux and Normal Renal Tracts (PRIVENT) trial.2 Despite differences in the study populations of the PRIVENT trial and the RIVUR trial, the results were consistent (hazard ratio for the risk of recurrence of urinary tract infection, 0.61; 95% confidence interval [CI], 0.40 to 0.93 vs. 0.5; 95% CI, 0.34 to 0.74).

In the RIVUR trial, 80 of 605 participants (13%) were lost to follow-up. This loss was nondifferential, so it was unlikely to bias results, but imputed outcomes based on best or worst scenarios are unusual and their inclusion in the Abstract was surprising.
Original languageEnglish
Pages (from-to)1070-1073
Number of pages4
JournalNew England Journal of Medicine
Issue number11
Publication statusPublished - 11 Sept 2014


  • Veiscoureteral reflux (RIVUR)
  • Children
  • Pediatrics
  • Urinary tract infection (UTI)
  • Antibiotics


Dive into the research topics of 'Antimicrobial prophylaxis for children with vesicoureteral reflux'. Together they form a unique fingerprint.

Cite this